Literature DB >> 11212249

Increased retinoic acid responsiveness in lung carcinoma cells that are nonresponsive despite the presence of endogenous retinoic acid receptor (RAR) beta by expression of exogenous retinoid receptors retinoid X receptor alpha, RAR alpha, and RAR gamma.

H Wan1, W K Hong, R Lotan.   

Abstract

Nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are thought to mediate most of the effects of retinoids on cell growth and differentiation. Despite expressing abundant levels of RAR beta mRNA, lung adenocarcinoma H1792 cells are resistant to the growth-inhibitory effects of all-trans-retinoic acid, suggesting that they have a defect in retinoid signaling. To determine whether transfection of exogenous receptors can restore retinoid responsiveness, we transiently transfected into H1792 cells coexpression vectors containing cDNAs of cell surface antigen CD7 and either RAR alpha, RAR beta, RAR gamma, or RXR alpha. The cells were then treated with retinoids and incubated with 5'-bromo-2'-deoxyuridine. Cells that express exogenous receptor were identified using antibodies against CD7, and cells that synthesized DNA were identified with anti-5'-bromo-2'-deoxyuridine antibodies using secondary antibodies with red and green fluorescence, respectively. RXR alpha and RAR alpha enhanced growth inhibition by all-trans-retinoic acid or 9-cis-retinoic acid, whereas RAR gamma was less effective, and RAR beta was ineffective. The effects of the transfected receptors were associated with antagonism of activator protein 1 (AP-1) activity. Studies with RXR alpha deletion and point mutants indicated that growth suppression is: (a) dependent on intact DNA-binding and ligand-binding regions but not on the NH2-terminal region, which contains a ligand-independent transactivation function; (b) dependent on RXR homodimer formation and transactivation of RXR response element; and (c) associated with AP-1 antagonism. These results demonstrate that transfected receptors can restore responsiveness to retinoids by antagonizing AP-1 in H1792 cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212249

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha.

Authors:  Harish Srinivas; Denise M Juroske; Shailaja Kalyankrishna; Dianna D Cody; Roger E Price; Xiao-Chun Xu; Ramesh Narayanan; Nancy L Weigel; Jonathan M Kurie
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

2.  Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.

Authors:  Donna E Seabloom; Arthur R Galbraith; Anna M Haynes; Jennifer D Antonides; Beverly R Wuertz; Wendy A Miller; Kimberly A Miller; Vernon E Steele; Chen S Suen; M Gerard O'Sullivan; Frank G Ondrey
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-19

3.  Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.

Authors:  Iván P Uray; Qiang Shen; Hye-Sook Seo; HeeTae Kim; William W Lamph; Reid P Bissonnette; Powel H Brown
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

4.  Functional activation of PPARγ in human upper aerodigestive cancer cell lines.

Authors:  Simon K Wright; Beverly R Wuertz; George Harris; Raed Abu Ghazallah; Wendy A Miller; Patrick M Gaffney; Frank G Ondrey
Journal:  Mol Carcinog       Date:  2016-03-21       Impact factor: 4.784

5.  Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.

Authors:  Daniela Bonofiglio; Erika Cione; Hongyan Qi; Attilio Pingitore; Mariarita Perri; Stefania Catalano; Donatella Vizza; Maria Luisa Panno; Giuseppe Genchi; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

6.  High SLC2A1 expression associated with suppressing CD8 T cells and B cells promoted cancer survival in gastric cancer.

Authors:  Kyueng-Whan Min; Dong-Hoon Kim; Byoung Kwan Son; Kyoung Min Moon; So Myoung Kim; Md Intazur Rahaman; So Won Kim; Eun-Kyung Kim; Mi Jung Kwon; Young Wha Koh; Il Hwan Oh
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

7.  The Sin3A/MAD1 Complex, through Its PAH2 Domain, Acts as a Second Repressor of Retinoic Acid Receptor Beta Expression in Breast Cancer Cells.

Authors:  Nisha Rani Dahiya; Boris A Leibovitch; Rama Kadamb; Nidhi Bansal; Samuel Waxman
Journal:  Cells       Date:  2022-03-31       Impact factor: 6.600

Review 8.  Retinoic Acids in the Treatment of Most Lethal Solid Cancers.

Authors:  Lara Costantini; Romina Molinari; Barbara Farinon; Nicolò Merendino
Journal:  J Clin Med       Date:  2020-01-28       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.